Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597 603. S5-32. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664 9. S5-33. Richardson K, Schoen M, French B, et al. Statins and cogni- tive function: a systematic review. Ann Intern Med. 2013;159: 688 97. S5-34. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S6-1. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111 5. S6-2. Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making. 2010;30:176 88. S6-3. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combina- tion strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918 29. S6-4. van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. S6-5. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e122 37. S6-6. Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation a scoping review. Healthcare (Basel) 2016;4. S6-7. 